Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Peter J Barry

2PUBLICATIONS
15CO-AUTHORS
Fluid-structure interaction and aeroacousticsReaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|May 30, 2025
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis.

Rosemary E Maher, Urszula M Cytlak-Chaudhuri, Saad Aleem

|Nov 15, 2023
Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM.

Daniel Tewkesbury, Andrew M Jones, Rowland Bright-Thomas

Pageof 1

Frequent Collaborators

1 joint publications

Urszula M Cytlak-Chaudhuri

1 joint publications

Saad Aleem

1 joint publications

Daniel Paul Brice

1 joint publications

Eva Caamaño Gutiérrez

1 joint publications

Kimberley Driver

1 joint publications

Edward Emmott

1 joint publications

Alexander Rothwell

1 joint publications

Emily Smith

1 joint publications

Mark Travis

1 joint publications

Dave Lee

Frequent Collaborators

1 joint publications

Urszula M Cytlak-Chaudhuri

1 joint publications

Saad Aleem

1 joint publications

Daniel Paul Brice

1 joint publications

Eva Caamaño Gutiérrez

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.4K
See more related videos

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.4K
See more related videos